PALVELLA THERAPEUTICS, INC.

PVLA

$1.09B

Small Cap

NASDAQBiotechnology🇺🇸North America14 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jan 15, 2026

27d

Drug Pipeline

Drug Name	Phase	Indication	Designations
Vehicle	Phase 3	Pachyonychia Congenita	-
Placebo	Phase 3	Pachyonychia Congenita	-
QTORIN 3.9% Rapamycin Anhydrous Gel	Phase 3	Microcystic Lymphatic Malformation	-
PTX-022	Phase 3	Pachyonychia Congenita	-
Vehicle comparator	Phase 2	BCCs in Gorlin Syndrome Patients	-

Catalyst Timeline

1 upcoming, 1 past

⭐Phase 3Next

January 2026~QTORIN 3.9% Rapamycin Anhydrous Gel

Primary completion for QTORIN 3.9% Rapamycin Anhydrous Gel trial (NCT06239480) in Microcystic Lymphatic Malformation

Regulatory Approvals

PVLA News